The Endocannabinoid System and Parkinson Disease
Authors:
- Andrea GiuffridaAGAndrea Giuffrida
- Alex MartinezAMAlex Martinez
- 1 January 2017
- book chapter
- Published by Elsevier
- p. 63-81
Abstract
No abstract availableThis publication has 140 references indexed in Scilit:
- The cannabinoid agonist WIN55212-2 decreases l-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated ratsNeuroscience Research, 2012
- RGS4 Is Required for Dopaminergic Control of Striatal LTD and Susceptibility to Parkinsonian Motor DeficitsNeuron, 2012
- The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptorsNature Neuroscience, 2010
- In vivo pharmacology of endocannabinoids and their metabolic inhibitors: Therapeutic implications in Parkinson's disease and abuse liabilityProstaglandins & Other Lipid Mediators, 2010
- Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the ratBrain Research Bulletin, 2010
- Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2Neurochemistry International, 2009
- Multiple pathways involved in the biosynthesis of anandamideNeuropharmacology, 2008
- Inhibition of striatal dopamine release by CB1 receptor activation requires nonsynaptic communication involving GABA, H2O2, and KATP channelsNeurochemistry International, 2008
- Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: Role of CB1 and TRPV1 receptorsExperimental Neurology, 2007
- Inactivation of N-Acyl Phosphatidylethanolamine Phospholipase D Reveals Multiple Mechanisms for the Biosynthesis of EndocannabinoidsBiochemistry, 2006